Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Lamisil, Janssen Sporanox Liver Toxicity Warning Added To Labeling

Executive Summary

Novartis Lamisil patients should be assessed for pre-existing liver disease before receiving the antifungal tablets, revised labeling recommends.

You may also be interested in...



Watson Ferrlecit Cancer Study With Epoetin Will Enter Phase II By Year-End

Watson Pharmaceuticals plans to initiate a Phase II trial of Ferrlecit for cancer patients by the year-end.

Watson Ferrlecit Cancer Study With Epoetin Will Enter Phase II By Year-End

Watson Pharmaceuticals plans to initiate a Phase II trial of Ferrlecit for cancer patients by the year-end.

Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted

Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.

UsernamePublicRestriction

Register

PS037835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel